U.S. flag

An official website of the United States government

GRCh37/hg19 22q13.2-13.33(chr22:42955616-51183840)x1 AND not provided

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Mar 1, 2021
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000684529.2

Allele description [Variation Report for GRCh37/hg19 22q13.2-13.33(chr22:42955616-51183840)x1]

GRCh37/hg19 22q13.2-13.33(chr22:42955616-51183840)x1

Genes:
Variant type:
copy number loss
Cytogenetic location:
22q13.2-13.33
Genomic location:
Chr22: 42955616 - 51183840 (on Assembly GRCh37)
Preferred name:
GRCh37/hg19 22q13.2-13.33(chr22:42955616-51183840)x1
HGVS:
NC_000022.10:g.(?_42955616)_(51183840_?)del

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: CN517202

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000812052Quest Diagnostics Nichols Institute San Juan Capistrano
no assertion criteria provided
Pathogenic
(Mar 1, 2021)
germlineclinical testing

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From Quest Diagnostics Nichols Institute San Juan Capistrano, SCV000812052.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

Deletions of chromosome 22q13.3, including SHANK3, are associated with Phelan-McDermid syndrome (PHMDS; 22q13.3 deletion syndrome) (OMIM #606232). The common clinical features include neonatal hypotonia, global developmental delay, absent or severely delayed speech, moderate to profound intellectual disability, autism spectrum disorder, normal to accelerated growth, and minor facial dysmorphism. Deletion sizes of chromosome 22q13.3 are highly variable ranging from 0.22 to 9 Mb with no common breakpoints. The SHANK3 (SH3 and multiple ankyrin repeat domains protein 3; previously known as PROSAP2) gene has been deleted in all reported cases with Phelan-McDermid syndrome (Phelan K, Rogers RC. Phelan-McDermid Syndrome. 2005 May 11 [GeneReviews [Internet]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1198/.; Phelan K and McDermid HE. The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome). Mol Syndromol. 2012;2(3-5):186-201).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Mar 26, 2023